Cipla was founded as The Chemical, Industrial, & Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935; the founder's sons now head the company. Cipla is a market-leading medicine maker in India. The company has roughly 5,500 pharmaceutical products. Some are sold domestically, while the rest reach international markets in some 170 countries. It offers prescription drugs for all kinds of ailments -- arthritis, cancer, depression -- as well as over-the-counter drugs for colds, oral hygiene, and skin care. Cipla leads the domestic retail pharmaceutical market. The firm also makes bulk drugs, agrochemicals, and animal products. It has eight manufacturing plants located throughout the country.

IBEX Technologies Inc. company develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX also provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where sales revenues are split evenly. The publicly-traded company, founded in 1972, is led by CEO Paul Baehr.

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.

GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.

Pharmos Corporation was founded in 1990 and is headquartered in Iselin, New Jersey. Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutic drugs to treat a range of diseases of the nervous system in the United States and Israel. It focuses on the diseases of the nervous system, such as the disorders of the brain-gut axis, pain/inflammation, and autoimmune disorders. Pharmos's lead product candidate includes dextofisopam, a non-serotonergic agent, which is in Phase IIb clinical trials for the treatment of irritable bowel syndrome (IBS). Its product pipeline also includes VPI-013 that completed Phase IIa testing for the treatment of female sexual dysfunction and neuropathic pain; CB2-selective cannabinoids for the treatment of inflammatory/autoimmune diseases; and Tianeptine, which is in Phase I clinical trials for the treatment of IBS and functional dyspepsia. In addition, Pharmos Corporation's products under development comprise Cannabinor that has completed two Phase IIa proof of principle trials for treating pain; and NanoEmulsion drug delivery system, which is in Phase IIa clinical trial for the treatment of knee osteoarthritis. Pharmos's therapeutic drugs are also used to treat autoimmune disorders.

Mediatech, Inc. company develops, manufactures, and distributes molecular biology and cell culture reagents used by research labs. Its customers include pharmaceutical companies, government agencies, and academic institutions. Mediatech's products are sold under the cellgro and Insectagro brands, and include cell culture media, reagents, salt solutions, antibiotics, and bioprocess collection containers. The company also provides custom formulation and contract manufacturing services. Its products are sold in the US through its own sales force and through third-party distributors internationally. Mediatech was formed in 1984.

Catalent Pharma Solutions, Inc. provides proprietary drug delivery and packaging technologies, and outsourced services to pharmaceutical, biotechnology, and consumer healthcare companies worldwide. It operates in three segments: Oral Technologies, Sterile Technologies, and Packaging Services. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products, which are used in various customer products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as tablets and capsules. The Sterile Technologies segment produces various sterile dose forms used in the prescription drug and biologic market.This segment provides formulation and development for injectables, as well as lyophilization for otherwise unstable drugs and biologics. It also fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats; and offers blow-fill-seal technology. In addition, this segment offers biologic cell line development, analytical, and scientific consulting services, as well as provides services for inhaled products. The Packaging Services segment provides various contract packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit-doses; printed components services, such as creating package inserts or folding cartons; and clinical trial supply services providing packaging, and inventory and logistics management for clinical trials. The company has a strategic alliance with Endotis Pharma to develop oral formulations of synthetic oligosaccharides. The company is based in Somerset, New Jersey.

BD Biosciences company, a division of medical equipment firm Becton, Dickinson (BD), provides research supplies to the life sciences market. Its primary Cell Analysis unit offers cell imaging devices, flow cytometers (for cell sorting), and chemical reagents and antibodies (proteins) for cellular analysis. The Discovery Labware unit makes basic lab supplies including pipettes, tubes, and cell culture kits. In addition to scientific researchers and drug developers, BD Biosciences counts among its customers blood banks, hospitals, and clinical labs. The company sells its goods around the world through direct and indirect marketing reps and independent distributors.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.

Mirus Bio provides gene transfer technologies to the pharmaceutical industry. The company's reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. Besides its kits, Mirus Bio is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Mirus Bio has agreed to be acquired by Roche Holding for $125 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.